Alessandro Del Conte
ScholarGPS® ID: 95832675658166
Affiliation History
Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Lung Cancer | Non-small-cell Lung Carcinoma | Thorax | Radiation Therapy | Radiation | Chemotherapy | Mesothelioma | Colorectal Cancer | Pleural Effusion | Breast Cancer
Metrics Summary
Publication Count
105
Predicted Citations
1,381
Predicted h-index
20
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Targeted Therapy in Mesotheliomas: Uphill All the Way (journal article) Cancers, volume 16, issue 11, pages 1971- (2024). |
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC (journal article) Frontiers in Oncology, volume 14 (2024). |
Annals of Oncology, volume 34 (2023). |
International Journal of Molecular Sciences, volume 24, issue 14, pages 11495- (2023). |
International Journal of Molecular Sciences, volume 24, issue 13, pages 10803- (2023). |
Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC (journal article) Journal of Thoracic Oncology, volume 18, issue 2, pages e11-e13 (2023). |
Cancers, volume 14, issue 24, pages 6074- (2022). |
EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World (journal article) Journal of Thoracic Oncology, volume 17, issue 9, pages S450-S451 (2022). |
Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials (journal article) International Journal of Molecular Sciences, volume 23, issue 13, pages 7222- (2022). |
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? (journal article) International Journal of Molecular Sciences, volume 23, issue 13, pages 6936- (2022). |
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications (journal article) International Journal of Molecular Sciences, volume 23, issue 12, pages 6832- (2022). |
NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease (journal article) International Journal of Molecular Sciences, volume 23, issue 12, pages 6748- (2022). |
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era (journal article) International Journal of Molecular Sciences, volume 23, issue 12, pages 6477- (2022). |
First-Line Osimertinib in Patients with EGFR -Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study (journal article) The Oncologist, volume 27, issue 2, pages 87-e115 (2022). |
2021 IEEE/ACM 25th International Symposium on Distributed Simulation and Real Time Applications (DS-RT) (2021) Valencia, Spain |
Brigatinib as a treatment of ALK-positive non-small cell lung cancer (journal article) Expert Review of Precision Medicine and Drug Development, volume 6, issue 5, pages 299-305 (2021). |
Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines (journal article) Future Oncology, volume 17, issue 19, pages 2513-2527 (2021). |
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC (journal article) Journal of Thoracic Oncology, volume 16, issue 5, pages e31-e32 (2021). |
International Journal of Radiation Oncology*Biology*Physics, volume 109, issue 5, pages 1368-1376 (2021). |